Fig. 4
From: Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer
miR-26a-5p directly targets the 3’UTR of BARD1 and NABP1. A MicroT-CDS software was used to predict the downstream gene of miR-26a-5p. DDR gene sets were selected from GSEA randomly and then overlapped the three gene sets and got three potential target genes, HMGA1, NABP1 and BARD1. B BARD1 and NABP1 proteins were restrained after overexpressing miR-26a-5p in MDA-MB-231 and BT549 cells measured by Western blot. C, D TargetScan website was used to predict binding sites of miR-26a-5p and BARD1 mRNA. Dual-luciferase reporter assay was performed to confirm binding sites in 293T cells. E, F TargetScan website was used to predict binding sites of miR-26a-5p and NABP1 mRNA. Dual-luciferase reporter assay was performed to confirm binding sites in 293T cells. G–J CCK8 was used to measured cytotoxicity of Cisplatin after knockdown BARD1 in shRNA and NABP1 in siRNA in TNBC cells, respectively. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. control. N.S not significant. n = 3